Liver resection surgery versus thermal ablation for colorectal liver metastases

ISRCTN ISRCTN52040363
DOI https://doi.org/10.1186/ISRCTN52040363
Secondary identifying numbers 20592
Submission date
09/03/2016
Registration date
09/03/2016
Last edited
11/05/2020
Recruitment status
Stopped
Overall study status
Stopped
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-comparing-surgery-ablation-treatment-people-bowel-cancer-spread-liver-lava

Contact information

Ms Julie Croft
Public

University of Leeds
Clinical Trials Research Unit
17 Springfield Mount
Leeds
LS2 9JT
United Kingdom

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleLAVA: Liver resection surgery versus thermal Ablation for colorectal liVer metAstases
Study acronymLAVA
Study objectivesThe aim of this study is to compare the effectiveness of liver resection surgery and thermal ablation for the treatment of colorectal liver metastases.
Ethics approval(s)16/LO/0058
Health condition(s) or problem(s) studiedTopic: Surgery; Subtopic: Surgery; Disease: Surgery (All Surgery)
InterventionParticipants are randomly allocated to one of two treatment groups.

Surgical resection: Surgical liver resection will be performed in accordance with each site’s usual practice. Patients may be offered open or laparoscopic liver resection depending on site and stage of disease. Procedures for patients with extensive metastatic disease can include two stage liver resection, venous embolization, or the ALPPS procedure (Associated Liver Partition and Portal vein ligation for Staged hepatectomy).

Thermal ablation: Either radiofrequency ablation (RFA) or microwave ablation (MWA) will be carried out according to the local availability of equipment and expertise. Ablation may be performed at laparoscopic or open surgery if the percutaneous approach is contra-indicated.
Intervention typeProcedure/Surgery
Primary outcome measureDisease free survival at 2 years is calculated from participant assessments at 3, 6, 12, 18 and 24 months post-randomisation
Secondary outcome measures1. Local and distant recurrence of disease at 2 years is calculated from participant assessments at 3, 6, 12, 18 and 24 months post-randomisation
2. Overall survival is determined at 2 and 5 years post-randomisation
3. Post treatment complications are recorded at participant assessments at 3, 6, 12, 18 and 24 months post-randomisation
4. Disease free survival (DFS) (measured from end of intervention) at 2 years post-randomisation
5. Use of subsequent therapies for treatment failure over 2 years post-randomisation
6. Health related quality of life is measured using EQ-5D, EORTC QLQ-C30, EORTC LMC21 at baseline 3 and 6 months post randomisation
7. Length of intensive therapy unit (ITU) and inpatient stay
8. Resource use collected retrospectively at 3, 6, 12, 18, and 24 months post-randomisation
Overall study start date01/10/2016
Completion date30/09/2020
Reason abandoned (if study stopped)Participant recruitment issue

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 330; UK Sample Size: 252
Total final enrolment9
Key inclusion criteria1. Aged ≥ 18 years
2. Able to provide written informed consent
3. MDT diagnosis of colorectal liver metastases considered to be resectable with curative intent
4. Resected colorectal primary or plan for primary resection with curative intent
5. Meets one or more of the following criteria:
5.1. Considered high risk for surgery due to age e.g. Age greater than 75 years of age
5.2. Major co-morbidities as judged by the treating clinician. Examples include history of myocardial infarction, severe chronic airway disease, major cerebrovascular accidents (CVA), pulmonary embolism (PE)
5.3. Liver metastases with poor prognosis and or high risk surgery due to tumour burden, Examples include extensive synchronous disease, need for two stage resection or ALLPS, small anticipated remnant liver volume, resectable or ablatable extra-hepatic disease, downstaged with chemotherapy, poor response after chemotherapy or portal vein embolization but still resectable
6. Suitable candidate for either liver resection surgery or thermal ablation as judged by the MDT
7. Able and willing to comply with the terms of the protocol including QoL questionnaire
Key exclusion criteria1. Incurable extra-hepatic metastases
2. Concurrent malignant disease (except basal cell carcinoma)
3. Patients who have undergone previous surgery or ablation for colorectal liver metastases
4. Planned simultaneous resection for primary and liver metastases disease
5. Pregnancy
Date of first enrolment01/10/2016
Date of final enrolment30/09/2020

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

University of Leeds
Clinical Trials Research Unit
17 Springfield Mount
Leeds
LS2 9JT
United Kingdom

Sponsor information

University College London
Hospital/treatment centre

R&D (1st Floor, Maple House)
Rossenheim Building
235 Euston Road
London
NW1 2BU
England
United Kingdom

ROR logo "ROR" https://ror.org/02jx3x895

Funders

Funder type

Government

National Institute for Health Research
Government organisation / National government
Alternative name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
Location
United Kingdom

Results and Publications

Intention to publish date31/08/2019
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 13/02/2018 Yes No
Results article results 01/04/2020 11/05/2020 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

11/05/2020: Publication reference and total final enrolment number added.
23/11/2018: The trial was stopped on 31/08/2018 due to recruitment issues. The intention to publish date was changed from 30/09/2021 to 31/08/2019.
15/02/2018: Publication reference added.
20/03/2017: Cancer Help UK lay summary link added to plain English summary field.